Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

Rhea-AI Summary

Phathom Pharmaceuticals (PHAT) has announced it will report its third quarter 2024 financial results and provide a business update via live webcast on Thursday, November 7, 2024, at 8:30 am ET. The company, which focuses on developing and commercializing gastrointestinal disease treatments, will make the webcast available through their investor relations website, with a recording accessible for 90 days afterward. Phathom markets VOQUEZNA® tablets for various GERD treatments and H. pylori infection through their VOQUEZNA® TRIPLE PAK® and DUAL PAK® products.

News Market Reaction

+8.29%

1 alert

+8.29% News Effect

On the day this news was published, PHAT gained 8.29%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

• Management to host conference call on Thursday, November 7, 2024, at 8:30 am ET

FLORHAM PARK, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, November 7, 2024, to report its third quarter 2024 financial results and provide a business update.

A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the meeting.

About Phathom Pharmaceuticals, Inc. 
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA^® (vonoprazan) tablets for the treatment of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and associated heartburn, in addition to VOQUEZNA^® TRIPLE PAK^® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA^® DUAL PAK^® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

© 2024 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

FAQ

When will Phathom Pharmaceuticals (PHAT) report Q3 2024 earnings?

Phathom Pharmaceuticals will report its third quarter 2024 financial results on Thursday, November 7, 2024, at 8:30 am ET via a live webcast.

How can I access Phathom Pharmaceuticals (PHAT) Q3 2024 earnings webcast?

The earnings webcast can be accessed through the Events & Presentations section of Phathom's website at investors.phathompharma.com. A recording will be available for 90 days after the presentation.

What products does Phathom Pharmaceuticals (PHAT) currently market in the US?

Phathom markets VOQUEZNA® tablets for GERD treatment, VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® for H. pylori infection treatment in adults.